NCT01628549

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline Compared to Placebo in the Treatment of Facial Acne Vulgaris, Study PR-10411

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 285 (actual)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 12 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	50 mg P005672-HCl	P005672-HCl administered as an oral capsule(s) once daily
DRUG	Placebo	Dose-matched Placebo capsule administered as an oral capsule(s) once daily
DRUG	100 mg P005672-HCl	P005672-HCl administered as an oral capsule(s) once daily

Timeline

• Start date: 2012-06-30
• Primary completion: 2012-11-16
• Completion: 2013-01-31
• First posted: 2012-06-26
• Last updated: 2019-02-01
• Results posted: 2019-01-08

Locations

38 sites across 1 country: United States